Arcadia Biosciences
RKDA
21 hedge funds and large institutions have $6.54M invested in Arcadia Biosciences in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
0.06% more ownership
Funds ownership: 0.29% → 0.36% (+0.06%)
12% less capital invested
Capital invested by funds: $7.4M → $6.54M (-$858K)
22% less call options, than puts
Call options by funds: $619K | Put options by funds: $790K
22% less funds holding
Funds holding: 27 → 21 (-6)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$1.23M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$501K |
| 3 |
State Street
Boston,
Massachusetts
|
+$46.7K |
| 4 |
MA
MYDA Advisors
Woodmere,
New York
|
+$35.1K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$29.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$149K |
| 2 |
Goldman Sachs
New York
|
-$94K |
| 3 |
Jane Street
New York
|
-$58K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$32K |
| 5 |
PCM
Pinz Capital Management
New York
|
-$24K |
RKDA Hedge Fund Activity: Q3 2021 in Review
21 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q3 2021, worth a combined $6.54M — down 12% from $7.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of RKDA and 2 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was Ardsley Advisory Partners, adding an estimated $1.23M. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $149K sold.
- 21 institutional investors held Arcadia Biosciences (RKDA) as of Q3 2021, down from 27 in Q2 2021.
- Funds reported $6.54M of Arcadia Biosciences stock for Q3 2021, down 12% quarter-over-quarter.
- 2 funds opened new Arcadia Biosciences positions in Q3 2021 and 8 closed out, a net change of -6 holders.
- The largest Arcadia Biosciences buyer in Q3 2021 was Ardsley Advisory Partners, an estimated $1.23M added.
- The largest Arcadia Biosciences seller in Q3 2021 was Boothbay Fund Management, an estimated $149K sold.
Based on aggregated 13F filings for Q3 2021.